Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
NCT: NCT02584270 · RECRUITING
Brief Summary
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery. This is a robust scientific randomized prospective clinical trial. Positive outcomes from this study have the potential to dramatically alter the most common issues of oral cancer therapy, namely speech and swallowing functions. Patients will have been diagnosed with a cancer lesion of the tongue requiring surgery and removal of part of the tongue. Smaller cancers of the tongue are sized as T1 or T2. For patients with smaller lesions, a PAP, which can aid in speaking and swallowing, is not routinely provided.
Frequently Asked Questions
What is Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue?
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue is a clinical trial registered under NCT02584270. Current status: RECRUITING.
What is the status of NCT02584270?
The current status of NCT02584270 (Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue) is: RECRUITING.
When did Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue start?
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue started on 2018-01-02.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.